Listed by the USPTO as SHIAO, YIH-HORNG
Tech Center 1600 • Art Units: 1618 1621 1623 1672 1673 1691 1693
This examiner grants 73% of resolved cases
SHIAO, YIH-HORNG has 974 resolved cases in Tech Center 1600 and Art Unit 1618. The allowance rate is 72.6%, the interview lift is 75.9%, and the median time to allowance is 877 days. The interview measure is especially prominent in this profile, showing a strong positive association alongside a favorable allowance rate.
Boehringer Ingelheim International GmbH, Endeavor Biomedicines Inc., and AbbVie Inc. are the leading listed companies. FOLEY & LARDNER LLP, Morgan, Lewis & Bockius LLP (WA), and BakerHostetler are the leading listed firms. The 974 resolved cases give practitioners a broad record in which to study this pattern. Interview preparation may deserve significant attention, while the 877-day median remains important for prosecution scheduling.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18666922 | Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more SGLT-2 inhibitors and telmisartan | Non-Final OA | BOEHRINGER INGELHEIM VETMEDICA GMBH |
| 18594627 | SYSTEMS AND METHODS FOR DELIVERY OF LIQUID PHARMACEUTICAL COMPOSITIONS IN PARTICULAR COMPRISING ONE OR MORE SGLT-2 INHIBITOR(S) | Non-Final OA | Boehringer Ingelheim Vetmedica GmbH |
| 18742823 | BROMODOMAIN INHIBITORS | Non-Final OA | AbbVie Inc. |
| 18687149 | COMPOSITION FOR ENHANCING IMMUNOGENICITY | Non-Final OA | TORAY INDUSTRIES, INC. |
| 18700011 | SILICONE-MODIFIED PULLULAN, A COMPOSITION COMPRISING THE SAME, AND A COSMETIC | Non-Final OA | Shin-Etsu Chemical Co., Ltd. |
| 18225010 | METHODS FOR PRODUCING SYNTHETIC OLIGONUCLEOTIDES AND REMOVAL AGENTS FOR REMOVING IMPURITIES FROM ORGANIC WASH SOLVENTS USED IN OLIGONUCLEOTIDE SYNTHESIS | Final Rejection | Honeywell International Inc. |
| 18283408 | METHODS AND COMPOSITIONS FOR TREATING CANCER THERAPY-INDUCED NEUTROPENIC FEVER AND/OR GVHD | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18681728 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS | Non-Final OA | CORNELL UNIVERSITY |
| 18507851 | TUMOR IMMUNOTHERAPY | Non-Final OA | The Trustees of Columbia University in the City of New York |
| 18043254 | RNA STORAGE METHOD | Final Rejection | KAO CORPORATION |
| 18469530 | EXPANDING THE CHEMICAL SUBSTRATES FOR GENETIC CODE REPROGRAMMING | Non-Final OA | The Board of Trustees of the University of Illinois |
| 18733430 | METHOD FOR SEPARATING COMPONENTS USING SUPERCRITICAL FLUID CHROMATOGRAPH | Non-Final OA | OSAKA UNIVERSITY |
| 18714279 | HYALURONIC ACID POWDER | Non-Final OA | Kewpie Corporation |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy72.6% of resolved applications examined by Yih-Horng Shiao were allowed (974 resolved cases), compared with 33.1% across Art Unit 1618 over the last five years.
This examiner's interview lift is +75.9 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Yih-Horng Shiao took 877 days on average from filing to allowance.
Yih-Horng Shiao examines applications in Art Unit 1618 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
